Table 5 Infant outcomes between the TDF treatment and control groups.

From: Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads

Infants

   

Apgar score 1 min after birth, n (%)

  

0.613

  8~10 normal

55 (96.5%)

51 (98.1%)

 

  4~7 mild asphyxia

2 (3.5%)

1 (1.9%)

 

  0~3 severe suffocation

0

0

 

Weight (g)

3259.47 ± 369.03

3338.08 ± 363.04

0.265

Height (cm)

49.89 ± 0.82

49.92 ± 0.84

0.859

Congenital malformations, n (%)

0

0

 

Adverse reactions, n (%)

Fever

0

0

 

Cough

0

0

 

Vomiting

0

0

 

Jaundice

0

0

 

Laboratory examinations, n (%)

ALT (U/L)

22.25 ± 11.92

24.27 ± 18.83

0.501

HBsAg-positive

0

4 (7.7%)

0.033

HBeAg-positive

0

5 (9.6%)

0.017

HBV DNA-positive

0 (0%)

7 (13.5%)

0.004

Back to article page